Using ultrasound to evaluate white blood cell cancer in the skin

ISRCTN ISRCTN14038061
DOI https://doi.org/10.1186/ISRCTN14038061
Secondary identifying numbers 299-2019
Submission date
17/11/2019
Registration date
19/11/2019
Last edited
03/01/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions.
The diagnosis of Mycosis fungoides is often delayed since the skin lesions look similar to other skin diseases. While in many cases a diagnosis of skin diseases can be made clinically and does not require a skin biopsy, the diagnosis of Mycosis fungoides requires a skin biopsy and sometimes many skin biopsies are needed to make the correct diagnosis.
A possible new method for diagnosis is skin ultrasound, which is a fast method (done within minutes) and causes no harm or pain.

Who can participate?
Patients who have been diagnosed with Mycosis fungoides.

What does the study involve?
The study involves the application of ultrasound and dermoscopy (as non-invasive techniques) for the assessment of cutaneous lymphoma lesions.

What are the possible benefits and risks of participating?
There are no direct benefits for the patients and no potential risks of participation are anticipated.

Where is the study run from?
Sunnybrook Health Sciences Centre, Toronto, Canada

When is the study starting and how long is it expected to run for?
December 2019 to June 2021

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr Iris Wohlmuth-Wieser
iris.wohlmuthwieser@sunnybrook.ca
Dr Raed Alhusayen
raed.alhusayen@sunnybrook.ca

Contact information

Dr Iris Wohlmuth-Wieser
Scientific

2075 Bayview Ave
Toronto
M4N 3M5
Canada

ORCiD logoORCID ID 0000-0003-4714-838X
Phone +1 416 4804908
Email iris.wohlmuthwieser@sunnybrook.ca

Study information

Study designProspective single-center observational cohort study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeDiagnostic
Participant information sheet No participant information sheet available
Scientific titleThe implementation of novel imaging techniques for the evaluation of cutaneous lymphomas
Study acronymITCL
Study hypothesisThe aim of the study is to prospectively obtain high-frequency ultrasound images (HF-USG) in MF patients of different stages of the disease, in order to describe baseline HF-USG criteria for MF and to compare the HF-USG images with dermoscopy and macroscopic images from the same index skin lesion
Ethics approval(s)Approved 29/10/2019, Research Ethics Board, Sunnybrook Health Sciences Centre (2075 Bayview Ave, Toronto, M4N 3M5, Ontario, Canada; +1 416-480-6100; monica.hung@sunnybrook.ca), ref: 299-2019
ConditionMycosis fungoides (cutaneous lymphoma)
InterventionThe study is designed to investigate the applicability of HF-USG in patients with mycosis fungoides using Vevo MD®; FUJIFILM VisualSonics, Toronto, ON, Canada ultrasound machine and to describe baseline ultrasound charateristics for mycosis fungoides and to compare these findings with standard dermoscopy.

Non-invasive standard dermoscopy and ultrasound images will be obtained from an index lesion of the patient. The patient will remain under standard of care. There will be no additional biopsies obtained for study purposes. The investigators will only take non-invasive images as described above, thus not imposing any potential harm to the patient. The total duration of the observation is expected to take 30 minutes (one single visit). No follow-up visits are planned for this study.
Intervention typeDevice
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Vevo MD® ultrasound machine
Primary outcome measureUltrasound characteristics (morphology of the epidermis, dermis and subcutis) for mycosis fungoides measured using the Vevo MD® ultrasound machine at the time of investigation
Secondary outcome measuresDermoscopy characteristics (pattern of the skin lesion including the morphology of vessels, follicular openings and the color of scales) for mycosis fungoides measured using skin surface microspcopy at the time of investigation
Overall study start date01/11/2019
Overall study end date30/06/2021

Eligibility

Participant type(s)Patient
Age groupAll
SexBoth
Target number of participants30
Total final enrolment30
Participant inclusion criteriaPatch or plaque stage mycosis fungoides
Participant exclusion criteria1. Clinical suspicion of mycosis fungoides lacking definitive histopathologic proof
2. Mycosis fungoides with generalized erythroderma
Recruitment start date01/12/2019
Recruitment end date30/06/2021

Locations

Countries of recruitment

  • Canada

Study participating centre

Sunnybrook Health Sciences Centre
2075 Bayview Avenue
Toronto, ON
M4N 3M5
Canada

Sponsor information

Sunnybrook Health Sciences Centre
Hospital/treatment centre

2075 Bayview Ave
Toronto
M4N 3M5
Canada

Phone +1 416 480 4908
Email lyn.sarceda@sunnybrook.ca
Website https://sunnybrook.ca
ROR logo "ROR" https://ror.org/03wefcv03

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date01/08/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planWe plan to publish our data in a pubmed-listed journal.

The study protocol is available on request from the study contacts.
IPD sharing planAll data generated or analysed during this study will be included in the subsequent results publication.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 23/12/2020 03/01/2023 Yes No

Editorial Notes

03/01/2023: Publication reference added.
19/11/2019: Trial’s existence confirmed by Research Ethics Board, Sunnybrook Health Sciences Centre.